Moreover, some novel potential therapeutic targets of AD were identified as follows: CD33 on Monocytic Myeloid-Derived Suppressor Cells, CD33 on CD33 + HLA DR +CD14 dim, CD33 on CD33 + HLA DR+, CD33 on CD33 + HLA DR + CD14-, CD33 on CD33dim HLA DR -, CD33 on CD33dim HLA DR + CD11b-, and Myeloid cell surface antigen CD33 were positively associated with all the three main outcome traits of AD and the risk of LOAD. This evidence concerns the gene ITGAM and Alzheimer disease.